Future anti-CD44 investigations should look at earlier bladder cancer stages and in non-muscle-invasive disease, with the advantage of the latter being the ability to deliver the therapy intravesically, which will likely reduce side effects associated with systemic monoclonal antibody therapy. The gene discussed is CD44; the disease is urinary bladder carcinoma.